Skip to main content

Table 1 Percentage of patients with supraventricular tachycardia (SVT), ventricular tachycardia (VT) or increase in premature ventricular complexes (PCV) after receiving levosimendan or placebo

From: Effects of levosimendan on cardiac arrhythmia in patients with severe heart failure

 

SVT

VT

Increase in PCV

Levosimendan

5%

12%

8%

Placebo

5%

15%

9%